394 related articles for article (PubMed ID: 27664108)
1. Cost-Effectiveness of High Dose Hemodialysis in Comparison to Conventional In-Center Hemodialysis in the Netherlands.
Beby AT; Cornelis T; Zinck R; Liu FX
Adv Ther; 2016 Nov; 33(11):2032-2048. PubMed ID: 27664108
[TBL] [Abstract][Full Text] [Related]
2. High-dose hemodialysis versus conventional in-center hemodialysis: a cost-utility analysis from a UK payer perspective.
Liu FX; Treharne C; Arici M; Crowe L; Culleton B
Value Health; 2015 Jan; 18(1):17-24. PubMed ID: 25595230
[TBL] [Abstract][Full Text] [Related]
3. Lifetime cost-effectiveness analysis of first-line dialysis modalities for patients with end-stage renal disease under peritoneal dialysis first policy.
Wong CKH; Chen J; Fung SKS; Mok M; Cheng YL; Kong I; Lo WK; Lui SL; Chan TM; Lam CLK
BMC Nephrol; 2020 Feb; 21(1):42. PubMed ID: 32019528
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of haemodialysis and peritoneal dialysis for patients with end-stage renal disease in Singapore.
Yang F; Lau T; Luo N
Nephrology (Carlton); 2016 Aug; 21(8):669-77. PubMed ID: 26566750
[TBL] [Abstract][Full Text] [Related]
5. Economic evaluation of palliative management versus peritoneal dialysis and hemodialysis for end-stage renal disease: evidence for coverage decisions in Thailand.
Teerawattananon Y; Mugford M; Tangcharoensathien V
Value Health; 2007; 10(1):61-72. PubMed ID: 17261117
[TBL] [Abstract][Full Text] [Related]
6. The financial impact of increasing home-based high dose haemodialysis and peritoneal dialysis.
Liu FX; Treharne C; Culleton B; Crowe L; Arici M
BMC Nephrol; 2014 Oct; 15():161. PubMed ID: 25278356
[TBL] [Abstract][Full Text] [Related]
7. Hemodialysis for end-stage renal disease: a cost-effectiveness analysis of treatment-options.
Gonzalez-Perez JG; Vale L; Stearns SC; Wordsworth S
Int J Technol Assess Health Care; 2005; 21(1):32-9. PubMed ID: 15736512
[TBL] [Abstract][Full Text] [Related]
8. An operating cost comparison between conventional and home quotidian hemodialysis.
Kroeker A; Clark WF; Heidenheim AP; Kuenzig L; Leitch R; Meyette M; Muirhead N; Ryan H; Welch R; White S; Lindsay RM
Am J Kidney Dis; 2003 Jul; 42(1 Suppl):49-55. PubMed ID: 12830444
[TBL] [Abstract][Full Text] [Related]
9. Twenty-five years of experience with out-center hemodialysis.
Arkouche W; Traeger J; Delawari E; Sibaï-Galland R; Abdullah E; Galland R; Leitienne P; Fouque D; Laville M
Kidney Int; 1999 Dec; 56(6):2269-75. PubMed ID: 10594805
[TBL] [Abstract][Full Text] [Related]
10. Cost utility analysis of end stage renal disease treatment in Ministry of Health dialysis centres, Malaysia: Hemodialysis versus continuous ambulatory peritoneal dialysis.
Surendra NK; Abdul Manaf MR; Hooi LS; Bavanandan S; Mohamad Nor FS; Firdaus Khan SS; Meng OL; Abdul Gafor AH
PLoS One; 2019; 14(10):e0218422. PubMed ID: 31644577
[TBL] [Abstract][Full Text] [Related]
11. Health economic evaluations: the special case of end-stage renal disease treatment.
Winkelmayer WC; Weinstein MC; Mittleman MA; Glynn RJ; Pliskin JS
Med Decis Making; 2002; 22(5):417-30. PubMed ID: 12365484
[TBL] [Abstract][Full Text] [Related]
12. Direct and indirect costs of end-stage renal disease patients in the first and second years after initiation of nocturnal home haemodialysis, hospital haemodialysis and peritoneal dialysis.
Wong CKH; Chen J; Fung SKS; Mok MMY; Cheng YL; Kong I; Lo WK; Lui SL; Chan TM; Lam CLK
Nephrol Dial Transplant; 2019 Sep; 34(9):1565-1576. PubMed ID: 30668781
[TBL] [Abstract][Full Text] [Related]
13. The quality of life and cost utility of home nocturnal and conventional in-center hemodialysis.
McFarlane PA; Bayoumi AM; Pierratos A; Redelmeier DA
Kidney Int; 2003 Sep; 64(3):1004-11. PubMed ID: 12911550
[TBL] [Abstract][Full Text] [Related]
14. The Cost Effectiveness of High-Dose versus Conventional Haemodialysis: a Systematic Review.
Laplante S; Liu FX; Culleton B; Bernardo A; King D; Hudson P
Appl Health Econ Health Policy; 2016 Apr; 14(2):185-93. PubMed ID: 26691659
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness Analysis of High-Efficiency Hemodiafiltration Versus Low-Flux Hemodialysis Based on the Canadian Arm of the CONTRAST Study.
Lévesque R; Marcelli D; Cardinal H; Caron ML; Grooteman MP; Bots ML; Blankestijn PJ; Nubé MJ; Grassmann A; Canaud B; Gandjour A
Appl Health Econ Health Policy; 2015 Dec; 13(6):647-59. PubMed ID: 26071951
[TBL] [Abstract][Full Text] [Related]
16. The impact of home nocturnal hemodialysis on end-stage renal disease therapies: a decision analysis.
McFarlane PA; Bayoumi AM; Pierratos A; Redelmeier DA
Kidney Int; 2006 Mar; 69(5):798-805. PubMed ID: 16407887
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective.
Vegter S; Tolley K; Keith MS; Lok CE; Soroka SD; Morton AR
Clin Ther; 2012 Jul; 34(7):1531-43. PubMed ID: 22742885
[TBL] [Abstract][Full Text] [Related]
18. Renal transplantation vs hemodialysis: cost-effectiveness analysis.
Perović S; Janković S
Vojnosanit Pregl; 2009 Aug; 66(8):639-44. PubMed ID: 19780419
[TBL] [Abstract][Full Text] [Related]
19. Cost-Utility Analysis Using EQ-5D-5L Data: Does How the Utilities Are Derived Matter?
Yang F; Devlin N; Luo N
Value Health; 2019 Jan; 22(1):45-49. PubMed ID: 30661633
[TBL] [Abstract][Full Text] [Related]
20. The marginal cost of satellite versus in-center hemodialysis.
Soroka SD; Kiberd BA; Jacobs P
Hemodial Int; 2005 Apr; 9(2):196-201. PubMed ID: 16191069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
